Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2011

Open Access 01-12-2011 | Case report

Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report

Authors: Michelle CM Cheung, Robin L Jones, Ian Judson

Published in: Journal of Medical Case Reports | Issue 1/2011

Login to get access

Abstract

Introduction

Ifosfamide is a chemotherapy agent infrequently associated with liver toxicity. To the best of our knowledge, this report is the first to describe serious liver toxicity associated with ifosfamide used in combination with doxorubicin that caused acute but fully reversible liver failure and encephalopathy. This report reviews the possible mechanisms by which ifosfamide causes this adverse effect.

Case report

A 61-year-old Caucasian woman who presented with an inoperable right neck mass due to synovial sarcoma was treated with standard-dose ifosfamide and doxorubicin. Within 24 hours of completing the first cycle of chemotherapy, she developed significant derangements in liver function, with a 250-fold increase in transaminase and associated synthetic function impairment and encephalopathy. No other causes of liver failure were identified. Both biochemical tests and encephalopathy were reversed after supportive management and treatment with N-acetylcysteine. No liver toxicity was observed with subsequent cycles of chemotherapy with doxorubicin alone.

Conclusion

This case highlights the possibility that chemotherapy agents can cause rare and idiosyncratic toxicities, so physicians must be vigilant for drug reactions, especially when patients do not respond to usual treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kosmas C, Tsavaris N, Malamos N, Stavroyianni N, Gregoriou A, Rokana S, Polyzos A: Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br J Cancer. 2003, 88: 1168-1174. 10.1038/sj.bjc.6600887.CrossRefPubMedPubMedCentral Kosmas C, Tsavaris N, Malamos N, Stavroyianni N, Gregoriou A, Rokana S, Polyzos A: Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br J Cancer. 2003, 88: 1168-1174. 10.1038/sj.bjc.6600887.CrossRefPubMedPubMedCentral
3.
go back to reference Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM: Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000, 18: 3794-3803.PubMed Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM: Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000, 18: 3794-3803.PubMed
4.
go back to reference Mumtaz K, Azam Z, Hamid S, Abid S, Memon S, Ali Shah H, Jafri W: Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. Hepatol Int. 2009, 3: 563-570. 10.1007/s12072-009-9151-0.CrossRefPubMedPubMedCentral Mumtaz K, Azam Z, Hamid S, Abid S, Memon S, Ali Shah H, Jafri W: Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. Hepatol Int. 2009, 3: 563-570. 10.1007/s12072-009-9151-0.CrossRefPubMedPubMedCentral
5.
go back to reference King PD, Perry MC: Hepatotoxicity of chemotherapy. Oncologist. 2001, 6: 162-176. 10.1634/theoncologist.6-2-162.CrossRefPubMed King PD, Perry MC: Hepatotoxicity of chemotherapy. Oncologist. 2001, 6: 162-176. 10.1634/theoncologist.6-2-162.CrossRefPubMed
6.
go back to reference Norris S: Drug- and toxin-induced liver disease. Comprehensive Clinical Hepatology. Edited by: Bacon BR, O'Grady JG, DiBisceglie AM, Lake JR. 2006, St Louis: Mosby Elsevier, 497-516. 2CrossRef Norris S: Drug- and toxin-induced liver disease. Comprehensive Clinical Hepatology. Edited by: Bacon BR, O'Grady JG, DiBisceglie AM, Lake JR. 2006, St Louis: Mosby Elsevier, 497-516. 2CrossRef
7.
go back to reference Zhang J, Tian Q, Zhou SF: Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther. 2006, 1: 55-84. 10.2174/157488506775268515.CrossRef Zhang J, Tian Q, Zhou SF: Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther. 2006, 1: 55-84. 10.2174/157488506775268515.CrossRef
8.
9.
go back to reference Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S: The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007, 12: 1351-1360. 10.1634/theoncologist.12-11-1351.CrossRefPubMed Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S: The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007, 12: 1351-1360. 10.1634/theoncologist.12-11-1351.CrossRefPubMed
10.
go back to reference Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000, 82: 291-294. 10.1054/bjoc.1999.0917.CrossRefPubMedPubMedCentral Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000, 82: 291-294. 10.1054/bjoc.1999.0917.CrossRefPubMedPubMedCentral
Metadata
Title
Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report
Authors
Michelle CM Cheung
Robin L Jones
Ian Judson
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2011
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-5-180

Other articles of this Issue 1/2011

Journal of Medical Case Reports 1/2011 Go to the issue